Cargando...
Mutant p53 in cancer therapy—the barrier or the path
Since wild-type p53 is central for maintaining genomic stability and preventing oncogenesis, its coding gene TP53 is highly mutated in ~50% of human cancers, and its activity is almost abrogated in the rest of cancers. Approximately 80% of p53 mutations are single point mutations with several hotspo...
Gardado en:
| Publicado en: | J Mol Cell Biol |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Oxford University Press
2018
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6487791/ https://ncbi.nlm.nih.gov/pubmed/30508182 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jmcb/mjy072 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|